# Pinuccia Valagussa

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/pinuccia-valagussa/

## Facts

| Field | Value |
| --- | --- |
| Citations | 36,311 |
| Field | Breast Cancer Treatment Studies |
| h-index | 82 |
| i10-index | 219 |
| Last Known Institution | Fondazione Michelangelo |
| OpenAlex ID | https://openalex.org/A5061761089 |
| ORCID iD | https://orcid.org/0000-0003-3590-7916 |
| Works | 404 |

## Researcher papers

- [Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis](https://scholariq.org/papers/pathological-complete-response-and-long-term-clinical-benefit-in-breast-cancer/)
- [Combination Chemotherapy as an Adjuvant Treatment in Operable Breast Cancer](https://scholariq.org/papers/combination-chemotherapy-as-an-adjuvant-treatment-in-operable-breast-cancer/)
- [Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort](https://scholariq.org/papers/neoadjuvant-chemotherapy-with-trastuzumab-followed-by-adjuvant-trastuzumab/)
- [Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials](https://scholariq.org/papers/long-term-outcomes-for-neoadjuvant-versus-adjuvant-chemotherapy-in-early-breast/)
- [Recommendations From an International Expert Panel on the Use of Neoadjuvant (Primary) Systemic Treatment of Operable Breast Cancer: An Update](https://scholariq.org/papers/recommendations-from-an-international-expert-panel-on-the-use-of-neoadjuvant/)
- [Primary Chemotherapy To Avoid Mastectomy in Tumors With Diameters of Three Centimeters or More](https://scholariq.org/papers/primary-chemotherapy-to-avoid-mastectomy-in-tumors-with-diameters-of-three/)
- [High-Dose Chemotherapy and Autologous Bone Marrow Transplantation Compared with MACOP-B in Aggressive B-Cell Lymphoma](https://scholariq.org/papers/high-dose-chemotherapy-and-autologous-bone-marrow-transplantation-compared-with/)
- [Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials](https://scholariq.org/papers/trastuzumab-for-early-stage-her2-positive-breast-cancer-a-meta-analysis-of-13/)
- [Ten-year experience with CMF-based adjuvant chemotherapy in resectable breast cancer](https://scholariq.org/papers/ten-year-experience-with-cmf-based-adjuvant-chemotherapy-in-resectable-breast/)
- [Phase III Trial Evaluating the Addition of Paclitaxel to Doxorubicin Followed by Cyclophosphamide, Methotrexate, and Fluorouracil, As Adjuvant or Primary Systemic Therapy: European Cooperative Trial in Operable Breast Cancer](https://scholariq.org/papers/phase-iii-trial-evaluating-the-addition-of-paclitaxel-to-doxorubicin-followed-by/)
- [Feasibility and Tolerability of Sequential Doxorubicin/Paclitaxel Followed by Cyclophosphamide, Methotrexate, and Fluorouracil and Its Effects on Tumor Response as Preoperative Therapy](https://scholariq.org/papers/feasibility-and-tolerability-of-sequential-doxorubicin-paclitaxel-followed-by/)

## Researcher topics

- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [Lymphoma Diagnosis and Treatment](https://scholariq.org/topics/lymphoma-diagnosis-and-treatment/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)

## Researcher university

- [Fondazione Michelangelo](https://scholariq.org/institutions/fondazione-michelangelo/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.